Oppenheimer initiated coverage on Acasti Pharma with a new price target
$ACST
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/22/2021 | $6.00 | Outperform | Oppenheimer |
| 12/21/2021 | $6.00 | Outperform | Oppenheimer |
LAVAL, QC, June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced the appointment of W. Taylor Kimberly, MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board. "We are extremely pleased to add eminent physicians with a deep understanding of aSAH and neurocritical care to the Acasti Scientific Advisory Board," commented Prashant Kohli, CEO of Acasti. "As we continue to focus our efforts squarely on the advanc
LAVAL, QC, April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, today announced the appointment of Prashant Kohli as Acasti's new Chief Executive Officer, succeeding Jan D'Alvise. The parties have mutually agreed to part ways, and Ms. D'Alvise will be stepping down from the board. Prashant Kohli has served as Chief Commercial Officer of Acasti since 2022. Mr. Kohli has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Recently, Mr. Kohli was VP, Commercial Operations of Acasti and at Grace Therapeutics, p
LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated August 31, 2022 (the "Proxy Statement"), being Jean Marie (John) Canan, Jan D'Alvise, Donald Olds, Vimal Kavuru and Michael L. Derby were elected as directors of Acasti at the Meeting to serve for a te
Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00
Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Acasti Pharma Inc. (0001444192) (Filer)
EFFECT - Acasti Pharma Inc. (0001444192) (Filer)
4 - Acasti Pharma Inc. (0001444192) (Issuer)
3/A - Acasti Pharma Inc. (0001444192) (Issuer)
3 - Acasti Pharma Inc. (0001444192) (Issuer)
4/A - Acasti Pharma Inc. (0001444192) (Issuer)